Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Hereditary Sensory and Autonomic Neuropathies 3Endometrial Neoplasms 3Neoplasms 2Breast Neoplasms 2Neoplasm Metastasis 1Lung Neoplasms 1Head and Neck Neoplasms 1Genital Diseases 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Endometrioid 1Advanced Solid Tumor 1Advanced Nonhematologic Malignancies 1

Interventions

pembrolizumab 133Gemcitabine 101Paclitaxel 100Carboplatin 84Nivolumab 66Docetaxel 62Bevacizumab 62Cisplatin 57Pemetrexed 50Fluorouracil 49Cyclophosphamide 41Cetuximab 41trametinib 38venetoclax 37Leucovorin 37Irinotecan 37Sorafenib 35Capecitabine 35Ipilimumab 33Dexamethasone 32atezolizumab 31Erlotinib Hydrochloride 28130-nm albumin-bound paclitaxel 28Drug Therapy 27Epoetin Alfa 26Doxorubicin 25Oxaliplatin 24Albumin-Bound Paclitaxel 24Prednisone 23Rituximab 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Neoplasms × serabelisib × Clear all
NCT02625259 2018-01-08

A Study to Evaluate the Relative Bioavailability, Effect of Food, and Gastric Potential Hydrogen (pH) Modification on the Pharmacokinetics of TAK-117 (MLN1117) in Healthy Participants

Takeda

Phase 1 Completed
54 enrolled 16 charts
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT01449370 2017-03-09

Dose Escalation Study of TAK-117 (MLN1117) in Subjects With Advanced Cancer

Takeda

Phase 1 Completed
125 enrolled 46 charts

Neoplasms, Hereditary Sensory and Autonomic Neuropathies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡